STOCK TITAN

TLC - TLC STOCK NEWS

Welcome to our dedicated page for TLC news (Ticker: TLC), a resource for investors and traders seeking the latest updates and insights on TLC stock.

TLC is a prominent company specializing in innovative healthcare solutions. Established with the mission to enhance the quality of life, TLC has consistently delivered top-notch products and services in the medical field. The company’s core business revolves around the research, development, and commercialization of cutting-edge medical technologies and pharmaceutical products.

In recent years, TLC has made significant strides in the biotechnology sector, focusing on developing advanced drug delivery systems. Their flagship product, a novel transdermal drug delivery patch, has garnered widespread attention for its effectiveness and user-friendly design.

TLC’s financial health remains robust, with steady revenue growth and strategic investments in research and development. The company has formed key partnerships with leading pharmaceutical firms and research institutions to bolster its innovation pipeline. Current projects include a range of clinical trials aimed at addressing unmet medical needs in areas such as oncology, neurology, and infectious diseases.

Another important aspect of TLC’s operations is its commitment to sustainability and corporate social responsibility. The company has implemented green practices across its manufacturing processes and continually seeks ways to minimize its environmental footprint.

Overall, TLC stands out as a beacon of excellence in the healthcare sector, known for its dedication to improving patient outcomes and its forward-thinking approach to medical innovation.

Rhea-AI Summary

TLC (Nasdaq: TLC, TWO: 4152) reported a significant 214.2% increase in operating revenue for Q1 2021, totaling NT$37.6 million (US$1.3 million), compared to NT$12.0 million in Q1 2020. However, the net loss widened slightly to NT$218.2 million (US$7.7 million), a loss per share of NT$2.39 (US$0.08). Operating expenses rose by 13.0% to NT$253.8 million (US$8.9 million). The company maintained NT$1,080.0 million (US$37.9 million) in cash as of March 31, 2021. TLC is progressing with pivotal clinical trials and upcoming meetings with the FDA, alongside gaining recognition in corporate governance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

TLC has been recognized as a leader in corporate governance, ranking in the Top 5% among all Taiwan Stock Exchange and Taipei Exchange listed companies for the seventh consecutive year. This achievement underscores TLC's commitment to high standards in governance practices, particularly notable as it is the only biotech firm to secure this honor. Additionally, TLC ranks in the Top 5% of small and medium-sized enterprises with a market value of TWD 5-10 billion. The recognition will be honored at an award ceremony in June, alongside other top performers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

InspirMed Inc., a subsidiary of TLC (Nasdaq: TLC), has announced its participation at the 23rd International Society for Aerosols in Medicine (ISAM) Congress, presenting a poster on the advantages of its inhalable formulations ISPM21 and ISPM19. The presentation, titled 'A Strategy to Treat COVID-19 with Targeted Delivery of Inhalable Liposomal Antiviral Drugs,' will take place in Boise, Idaho, from May 22-26, 2021. ISPM21 is a liposomal formulation of GS-441524, and ISPM19 is based on hydroxychloroquine, both aimed at improving treatment accessibility for COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

TLC (NASDAQ: TLC, TWO: 4152), a clinical-stage pharmaceutical company, announced its participation in two upcoming virtual investor conferences. The HC Wainwright & Co Global Life Sciences Conference is scheduled for March 9-10, 2021, with on-demand presentations available from 7am ET on March 9. The Oppenheimer 31st Annual Healthcare Conference will take place on March 16-17, 2021, featuring a presentation on March 17 at 8am ET. TLC's corporate presentation will be accessible on their website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

TLC (Nasdaq: TLC, TWO: 4152) reported a net loss of NT$983.3 million (US$35.0 million) for the fiscal year 2020, up from NT$807.5 million (US$27.0 million) in 2019. Operating revenue fell by 51.3% to NT$101.9 million (US$3.6 million), while operating expenses rose by 8.4% to NT$1,113.3 million (US$39.6 million). Despite these challenges, TLC achieved significant milestones in its clinical trials, including completing patient enrollment for its osteoarthritis program and advancing its inhalable hydroxychloroquine treatment. The company also strengthened its financial position with NT$1,342.7 million (US$47.8 million) in cash as of December 31, 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

TLC (Nasdaq: TLC, TWO: 4152) has announced the enrollment of the first subject in its Phase I clinical trial for TLC19, an inhaled formulation of hydroxychloroquine (HCQ) targeting COVID-19. This randomized, blinded study aims to assess the safety and pharmacokinetics of TLC19 in 30 healthy volunteers at varying doses. Labeled as a promising approach, TLC19 demonstrated significant lung exposure in preclinical studies, potentially enhancing efficacy while minimizing systemic toxicity. The company is also progressing on GMP manufacturing for large-scale production in Taiwan and the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial covid-19
Rhea-AI Summary

TLC (Nasdaq: TLC, TWO: 4152) has received ethical and scientific approval for its Phase I clinical trial of TLC19, a novel inhalation therapy targeting COVID-19. The trial will assess safety, tolerability, and pharmacokinetics of inhaled TLC19 in healthy volunteers. The recent approval follows the acceptance of TLC's IND application with Taiwan's FDA. This initiative is part of Taiwan's 'Taiwan Can Help' strategy, aiming to provide effective treatments amidst the pandemic. The study is expected to yield critical data for future COVID-19 patient trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial covid-19
-
Rhea-AI Summary

SOUTH SAN FRANCISCO and TAIPEI, Sept. 21, 2020 – TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company, announced that President George Yeh and CMO Dr. George Spencer-Green will present at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on September 23, 2020, at 9:10am ET. The 40-minute presentation will cover company updates and data analyses on its pain programs, TLC599 and TLC590. The corporate presentation is accessible on the TLC website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, September 11, 2020 – TLC (Nasdaq: TLC, TWO: 4152) announced that President George Yeh will participate in a fireside chat with analyst Kristen Kluska at the Cantor Virtual Global Healthcare Conference on September 15, 2020, at 10:00 AM ET. The discussion will focus on TLC's ongoing projects, including TLC599 for osteoarthritis pain relief, TLC590 for postsurgical pain, and TLC19 for COVID-19 treatment and prevention. A recording will be available on TLC's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary

TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company, announced that its President, Mr. George Yeh, and Chief Medical Officer, Dr. George Spencer-Green, will present at HC Wainwright & Co’s 22nd Annual Global Investment Conference on September 14, 2020, at 10:00am ET. The presentation will cover company updates and analyses on pain programs TLC599 and TLC590. The corporate slide deck will be accessible on TLC’s website in the Investors section.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences

FAQ

What does TLC specialize in?

TLC specializes in innovative healthcare solutions, including advanced drug delivery systems and pharmaceutical products.

What are some recent achievements of TLC?

TLC's recent achievements include the development of a novel transdermal drug delivery patch and significant progress in clinical trials for various medical conditions.

How is TLC performing financially?

TLC has a robust financial health with steady revenue growth and substantial investments in research and development.

Who are TLC's key partners?

TLC has formed partnerships with leading pharmaceutical firms and research institutions to enhance its innovation pipeline.

What are TLC's current projects?

TLC is currently engaged in several clinical trials targeting oncology, neurology, and infectious diseases.

Is TLC committed to sustainability?

Yes, TLC is committed to sustainability and has implemented environmentally friendly practices in its operations.

What is TLC's flagship product?

TLC's flagship product is a novel transdermal drug delivery patch known for its effectiveness and ease of use.

How does TLC contribute to corporate social responsibility?

TLC actively engages in corporate social responsibility by minimizing its environmental footprint and supporting community health initiatives.

What is the focus of TLC's research and development?

TLC focuses on developing advanced medical technologies and pharmaceuticals to address unmet medical needs.

How can I stay updated on TLC's latest news?

You can stay updated on TLC's latest news by following their official website and subscribing to newsletters from stock market websites like StockTitan.

TLC

Nasdaq:TLC

TLC Rankings

TLC Stock Data

42.03M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Taiwan
Taipei